Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma

LIU Baojie; REN Li

doi:10.7619/jcmp.20240423

Journal of Clinical Medicine in Practice > 2024 > 28(11): 41-44. > DOI: 10.7619/jcmp.20240423

LIU Baojie, REN Li. Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma[J]. Journal of Clinical Medicine in Practice, 2024, 28(11): 41-44. DOI: 10.7619/jcmp.20240423

Citation:

PDF (648 KB)

Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma

LIU Baojie,
REN Li^,

Department of Hematology, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, 100070

More Information

Received Date: January 22, 2024
Revised Date: February 26, 2024
Available Online: June 17, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the impacts of drug administration processes on comfort, tolerability and adverse events in patients with chemotherapy for multiple myeloma.
Methods
A total of 113 patients with chemotherapy for multiple myeloma were randomly divided into control group (n=56) and observation group (n=57). The control group was treated with conventional drug administration procedures, while the observation group was treated with bortezomib subcutaneously by an optimized drug administration process. Comfort level, tolerability, adverse events and satisfaction rate for injection were compared between the two groups before and after intervention.
Results
After intervention, the observation group scored higher on the General Comfort Questionnaire (GCQ) for physiological dimension of (24.59±2.73), psychological dimension of (25.64±2.29), sociocultural dimension of (22.64±2.05), environmental of (11.79±1.37), and total score of (79.21±6.81) than (21.68±2.67), (22.05±2.16), (18.11±1.74), (9.42±1.46) and (63.52±6.34) respectively in the control group. Total chemotherapy course was (6.02±1.08) cycles in the observation group, which was less than (7.86±1.59) cycles in the control group, with a chemotherapy discontinuation rate of 8.77% versus 37.5%, and the full-dose and full-schedule chemotherapy completion rate of 96.49% versus to 82.14% between observation group and control group, and all the differences were statistical significant (P < 0.05). The overall incidence of liver-kidney function damage, thrombocytopenia, and peripheral neuropathy during medication administration was 3.51% in the observation group, which was significantly lower than 16.07% in the control group (P < 0.05). The satisfaction rate for injection in the observation group was 94.74%, which was significantly higher than 78.57% in the control group (P < 0.05).
Conclusion
Optimizing the drug administration process can improve patient's comfort and tolerability during chemotherapy for multiple myeloma, reduce the incidence rate of adverse reactions, and has a high satisfaction rate for injection.
- drug administration processes,
- multiple myeloma,
- chemotherapy,
- nursing,
- comfortable degree

FullText(HTML)

References (19)

References

[1]	GUZDAR A, COSTELLO C. Supportive care in multiple myeloma[J]. Curr Hematol Malig Rep, 2020, 15(2): 56-61. doi: 10.1007/s11899-020-00570-9
[2]	GENTILE M, MORABITO F, MARTINO M, et al. Chemotherapy-based regimens in multiple myeloma in 2020[J]. Panminerva Med, 2021, 63(1): 7-12.
[3]	MATEOS M V, SONNEVELD P, HUNGRIA V, et al. Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(8): 509-518. doi: 10.1016/j.clml.2019.09.623
[4]	ASHRAFI F, MOGHADDAS A, DARAKHSHANDEH A. Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma[J]. J Res Pharm Pract, 2020, 9(1): 56-59. doi: 10.4103/jrpp.JRPP_18_82
[5]	汪英颖, 刘尚勤. 多发性骨髓瘤诊治指南解读(2018年)[J]. 临床内科杂志, 2018, 35(7): 503-504. doi: 10.3969/j.issn.1001-9057.2018.07.024
[6]	李芳, 陈玲燕, 罗菊. 思维场疗法结合舒适护理在多发性骨髓瘤化疗患者中的应用[J]. 齐鲁护理杂志, 2022, 28(15): 101-104. doi: 10.3969/j.issn.1006-7256.2022.15.034
[7]	LIU Z Q, XIA H L, LI C J, et al. Incidence and risk of peripheral neuropathy caused by intravenous and subcutaneous injection of bortezomib[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2019, 27(5): 1654-1663.
[8]	王科, 苏梅芳, 王萌, 等. 硼替佐米不同给药途径治疗多发性骨髓瘤的疗效及其与周围神经病变的相关分析[J]. 临床内科杂志, 2022, 39(12): 846-847. doi: 10.3969/j.issn.1001-9057.2022.12.016
[9]	LI F, YAO F S, ZHU X J, et al. A randomized phase Ⅱ, open-label and multicenter study of combination regimens of bortezomib at two doses by subcutaneous injection for newly diagnosed multiple myeloma patients[J]. J Cancer Res Clin Oncol, 2019, 145(9): 2343-2355. doi: 10.1007/s00432-019-02967-3
[10]	钱晨, 张柳柳, 顾连兵, 等. 多学科合作模式在优化术中腹腔化疗给药流程中的应用[J]. 中华现代护理杂志, 2023, 29(14): 1909-1912. doi: 10.3760/cma.j.cn115682-20220406-01627
[11]	周江燕, 谢珺, 殷丹, 等. 部位轮换定时定位注射卡应用于多发性骨髓瘤患者皮下注射中的效果[J]. 国际护理学杂志, 2023, 42(3): 444-446. doi: 10.3760/cma.j.cn221370-20210626-00109
[12]	曹红花, 吴娜, 贺鸣, 等. 皮下注射硼替佐米为主化疗方案治疗多发性骨髓瘤[J]. 昆明医科大学学报, 2019, 40(5): 49-52. doi: 10.3969/j.issn.1003-4706.2019.05.009
[13]	柏杨, 占美, 魏春燕, 等. 皮下注射硼替佐米的有效性和安全性循证评价[J]. 中国医院药学杂志, 2019, 39(13): 1358-1362, 1374. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYZ201913010.htm
[14]	梁艳, 周海燕, 叶小聪, 等. Z径路法结合留置气泡技术减轻注射用鼠神经生长因子肌内注射时疼痛的效果评价[J]. 护士进修杂志, 2017, 32(7): 651-652. https://www.cnki.com.cn/Article/CJFDTOTAL-FSJX201707028.htm
[15]	曾卫强, 曲云婷, 闫其星, 等. 抗肿瘤药物药学监护路径的建立和应用[J]. 中国药房, 2016, 27(35): 5017-5020. doi: 10.6039/j.issn.1001-0408.2016.35.41
[16]	刘璐, 蒋开明. 腹部轮换定时定位注射卡在多发性骨髓瘤患者皮下注射中的应用[J]. 中华现代护理杂志, 2019, 25(25): 3268-3271. doi: 10.3760/cma.j.issn.1674-2907.2019.25.023
[17]	蒋海华, 粟东云, 奉赛芝, 等. Z型注射法结合留置气泡技术在注射氟维司群患者中的应用效果[J]. 解放军护理杂志, 2017, 34(23): 74-76. https://www.cnki.com.cn/Article/CJFDTOTAL-JFHL201723025.htm
[18]	王珣, 徐岚, 赵素芳, 等. 硼替佐米腹部皮下注射治疗多发性骨髓瘤的疗效及不良反应的护理[J]. 中华现代护理杂志, 2018, 24(12): 1450-1453. doi: 10.3760/cma.j.issn.1674-2907.2018.12.022
[19]	李媛, 傅荣, 叶红芳, 等. 硼替佐米皮下注射治疗多发性骨髓瘤给药流程设计与实践[J]. 护理学杂志, 2015, 30(23): 12-14. https://www.cnki.com.cn/Article/CJFDTOTAL-HLXZ201523005.htm

[1]	HOU Dandan, QU Li. The impact of professional pain management in improving postoperative pain and comfort in patients undergoing thoracotomy surgery[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 109-112, 116. DOI: 10.7619/jcmp.20233112
[2]	TAO Xinhua, TIAN Fengqin, YU Chunxiang, WANG Xiuzhi, HU Xiaoying, CHU Cheng, LU Hongyan, ZHOU Dayan. Effect of postoperative analgesia nursing on the comfort degree of laparotomy patients in hepatobiliary surgery department[J]. Journal of Clinical Medicine in Practice, 2017, (8): 106-109. DOI: 10.7619/jcmp.201708032
[3]	CHANG Jinling, CHANG Qianqian. Effect of time nursing on hemostasis efficacy and comfort degree of patients with digestive tract bleeding[J]. Journal of Clinical Medicine in Practice, 2016, (16): 44-46,50. DOI: 10.7619/jcmp.201616014
[4]	LI Jie, WANG Guitao, HU Suqing, LIU Suzhi, DING Ying. Analysis of two analgesia methods on the comfort degrees and the analgesic efficacy for elderly patients after thoracic surgery[J]. Journal of Clinical Medicine in Practice, 2016, (14): 66-68,75. DOI: 10.7619/jcmp.201614021
[5]	MA Jing. Effect of evidence-based nursing on postoperative non-incision pain and comfortable degree of patients with laparoscopic cholecystectomy[J]. Journal of Clinical Medicine in Practice, 2016, (10): 87-90. DOI: 10.7619/jcmp.201610028
[6]	FENG Rui. The effect of modified nursing on pressure ulcer and comfort of lateral position patients during operation[J]. Journal of Clinical Medicine in Practice, 2015, (20): 83-85,89. DOI: 10.7619/jcmp.201520026
[7]	HAN Fengping, LI Xiaoyun. Application of comfort nursing in treatment of patients with percutaneous nephrolithotomy lithotripsy[J]. Journal of Clinical Medicine in Practice, 2015, (14): 87-89. DOI: 10.7619/jcmp.201514028
[8]	ZHANG Yinghua. Influence of whole course nursing on health knowledge and comfort of patients with femoral neck fractures[J]. Journal of Clinical Medicine in Practice, 2014, (10): 55-57. DOI: 10.7619/jcmp.201410019
[9]	ZHANG Lu, LI Zhenglan. Influence of evidence-based nursing on postoperative comfort degree and complications in patients with urologic surgical procedures[J]. Journal of Clinical Medicine in Practice, 2014, (2): 53-55. DOI: 10.7619/jcmp.201402019
[10]	TIAN Feng-ling. The influence of individual psychological intervention on the comfort level of patients with kidney puncture[J]. Journal of Clinical Medicine in Practice, 2011, (10): 30-31. DOI: 10.3969/j.issn.1672-2353.2011.10.014

Cited By

Cited by

Periodical cited type(11)

1.	张媛媛，赵志杰，刘青，李鹏飞，苑文娟. 血清NT-pro-BNP、IGFBP-7和CTRP12在慢性心力衰竭患者中的水平及意义. 检验医学与临床. 2025(01): 107-111+118 .
2.	陈伟光，谢冠聪，李桂云，龚宇锋，徐文波，王悦宁，许香广. 利用半乳糖凝集素-3、N末端B型利钠肽原联合超声心动图评估心力衰竭预后的研究. 齐齐哈尔医学院学报. 2022(09): 862-865 .
3.	吴利杰，董发. 左卡尼汀治疗慢性心力衰竭患者的疗效及安全性. 实用临床医药杂志. 2020(02): 104-107 . 本站查看
4.	邓凡. BNP的检测在危重烧伤患者病情评估中的临床应用价值. 当代医学. 2020(18): 61-63 .
5.	李润琴，郑晓轩，柴慧. 左西孟旦联合复方丹参滴丸治疗慢性心力衰竭的临床研究. 中国药物与临床. 2020(23): 3949-3951 .
6.	孙婧，赵沱，刘亚荣. 自拟芪红汤在慢性心力衰竭患者康复治疗中的应用对心脏标记物、生活质量的影响. 四川中医. 2019(07): 86-88 .
7.	林傲，孙晗嫣，孙晗然，吕焕然，张钧宇，魏艳丽，王凤玲，黄佳滨. 半乳凝素3与超敏C反应蛋白在老年舒张性心力衰竭的相关性研究. 黑龙江医药科学. 2019(03): 45-46 .
8.	李振超. IL-27、树突状细胞在慢性心力衰竭患者外周血中的表达变化. 医学理论与实践. 2019(20): 3342-3343 .
9.	张建霞，杨培亮，王焕. 冠心病合并慢性心力衰竭患者GDF15、BNP、sST2的表达及其与心功能的相关性. 临床误诊误治. 2019(12): 67-71 .
10.	盛洋，郑学敏，王伟，沈盛晖. 酒石酸美托洛尔片联合左卡尼汀注射剂治疗慢性心力衰竭的临床研究. 中国临床药理学杂志. 2018(04): 410-413 .
11.	邓威. 血清Gal-3、NT-pro-BNP在慢性心力衰竭中的表达及临床意义. 中国民康医学. 2018(16): 20-21 .

Other cited types(0)

Get Citation

PDF

XML

Article views (121) PDF downloads (6) Cited by(11)

Turn off MathJax

Article Contents

Abstract

References

Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma

Abstract

References

Related Articles

Cited by

Periodical cited type(11)

Other cited types(0)

Catalog

Effect of drug administration process optimization in patients with chemotherapy for multiple myeloma

Abstract

References

Related Articles

Cited by

Periodical cited type(11)

Other cited types(0)

Catalog

Export File

Citation

Format

Content